Opiates are important for the treatment of pain, but their abuse presents a major health problem due to their association with the recent HIV epidemic. Understanding the actions opiates in vivo is crucial to their rational use clinically and the development of potential treatments for abuse. Opiates and the opioid peptides act through a family of receptors, of which at least three opioid receptors have been cloned: mu, delta and kappa1. Studies on the actions of these receptors carried out in tissue culture have provided important information regarding their biochemistry and second messenger systems. However, this approach cannot address many questions regarding their actions within an integrated nervous system. The current application proposes to explore the actions of these receptors in vivo. Antisense approaches will be utilized to correlate the cloned opioid receptors with opioid pharmacology. Initial studies from our laboratory demonstrate that antisense oligodeoxynucleotides (ODN) directed against delta, mu or kappa1 receptors selectively and specifically downregulate their own receptor without interfering the function of the others. Mismatch ODN controls are inactive. This approach will be validated, looking at the uptake and stability of the various ODN's in tissue culture and in vivo as well as establishing the criteria to optimize their use. Antisense ODN's then will be used to examine the receptors responsible for a variety of opioid actions, including analgesia, respiratory depression and the inhibition of gastrointestinal transit. The second component of this application addresses the issue of tolerance. This work will expand on previous observations that NMDA antagonists and nitric oxide synthase (NOS) inhibitors can prevent or reverse morphine tolerance. Additional agents will be examined and the role of NOS studied using a knockout mouse. Finally, regional interactions important in opioid analgesia will be explored. Opiates act through the activation of multiple brain and spinal regions simultaneously. These interactions and the existence of synergy will be explored. Studies demonstrating intrinsic brainstem synergy will be expanded and additional experiments will explore the mu/delta synergy between brainstem regions recently observed by our group. Overall, this proposal will provide important information correlating recent advances in the molecular biology of opioid receptors with their pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37DA007242-09
Application #
2897844
Study Section
Special Emphasis Panel (SRCD (03))
Program Officer
Lin, Geraline
Project Start
1991-06-01
Project End
2000-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Le Rouzic, Valerie; Narayan, Ankita; Hunkle, Amanda et al. (2018) Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic. Anesth Analg :
Baumann, Michael H; Majumdar, Susruta; Le Rouzic, Valerie et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134:101-107
Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2018) Truncated ?-Opioid Receptors With 6 Transmembrane Domains Are Essential for Opioid Analgesia. Anesth Analg 126:1050-1057
Marrone, Gina F; Le Rouzic, Valerie; Varadi, Andras et al. (2017) Genetic dissociation of morphine analgesia from hyperalgesia in mice. Psychopharmacology (Berl) 234:1891-1900
Pasternak, Gavril W (2017) Allosteric Modulation of Opioid G-Protein Coupled Receptors by Sigma1 Receptors. Handb Exp Pharmacol 244:163-175
Kim, Felix J; Pasternak, Gavril W (2017) Cloning the sigma2 receptor: Wandering 40 years to find an identity. Proc Natl Acad Sci U S A 114:6888-6890
Xu, Jin; Lu, Zhigang; Narayan, Ankita et al. (2017) Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine. J Clin Invest 127:1561-1573
Urai, Ákos; Váradi, András; Sz?cs, Levente et al. (2017) Synthesis and pharmacological evaluation of novel selective MOR agonist 6?-pyridinyl amidomorphines exhibiting long-lasting antinociception. Medchemcomm 8:152-157
Marrone, Gina F; Lu, Zhigang; Rossi, Grace et al. (2016) Tetrapeptide Endomorphin Analogs Require Both Full Length and Truncated Splice Variants of the Mu Opioid Receptor Gene Oprm1 for Analgesia. ACS Chem Neurosci 7:1717-1727
Grinnell, Steven G; Ansonoff, Michael; Marrone, Gina F et al. (2016) Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants. Synapse 70:395-407

Showing the most recent 10 out of 50 publications